1-2 of 2
Kai Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors

Haiying Cheng, Yiyu Zou, Jeffrey S. Ross, Kai Wang, Xuewen Liu, Balazs Halmos, Siraj M. Ali, Huijie Liu, Amit Verma, Cristina Montagna, Abraham Chachoua, Sanjay Goel, Edward L. Schwartz, Changcheng Zhu, Jidong Shan, Yiting Yu, Kira Gritsman, Roman Yelensky, Doron Lipson, Geoff Otto, Matthew Hawryluk, Philip J. Stephens, Vincent A. Miller, Bilal Piperdi, Roman Perez-Soler
Journal: Cancer Discovery
Cancer Discov (2015) 5 (12): 1262–1270.
https://doi.org/10.1158/2159-8290.CD-14-0971
Published: 03 December 2015
View articletitled, RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors
Open the PDF for RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors in another window
Includes: Supplementary data
Journal Articles

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Justin M. Balko, Jennifer M. Giltnane, Kai Wang, Luis J. Schwarz, Christian D. Young, Rebecca S. Cook, Phillip Owens, Melinda E. Sanders, Maria G. Kuba, Violeta Sánchez, Richard Kurupi, Preston D. Moore, Joseph A. Pinto, Franco D. Doimi, Henry Gómez, Dai Horiuchi, Andrei Goga, Brian D. Lehmann, Joshua A. Bauer, Jennifer A. Pietenpol, Jeffrey S. Ross, Gary A. Palmer, Roman Yelensky, Maureen Cronin, Vincent A. Miller, Phillip J. Stephens, Carlos L. Arteaga
Journal: Cancer Discovery
Cancer Discov (2014) 4 (2): 232–245.
https://doi.org/10.1158/2159-8290.CD-13-0286
Published: 04 February 2014
View articletitled, Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
Open the PDF for Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets in another window
Includes: Supplementary data